By Inteledoc Expert Team | 10 min read | Dr. Naveen Satija, MBBS, FIAGES, DNB (Surgery)
Wegovy and Mounjaro are the two names dominating the global weight loss medicine conversation — and increasingly, the Indian one. Both are injectable weekly medicines. Both work through gut hormone pathways. Both produce significant, lasting weight loss in properly supervised programmes. But they are not the same medicine, they do not produce identical results, and choosing between them is a clinical decision that deserves a proper explanation. This is that explanation.
The Fundamental Biological Difference
Activates GLP-1 receptors. GLP-1 is the gut hormone that signals the brain you are full, slows stomach emptying, and stabilises blood sugar. One hormone pathway, one receptor type. Highly effective. 15+ years of clinical evidence.
Activates both GLP-1 and GIP receptors simultaneously. GIP is a second gut hormone that works alongside GLP-1 to regulate energy storage, insulin sensitivity, and fat metabolism. Two hormone pathways, two receptor types. The dual mechanism produces a broader and stronger metabolic effect than GLP-1 alone — which is the biological basis for Mounjaro’s stronger clinical trial results.
The Clinical Trial Numbers — What They Mean in Practice
✗ WEGOVY (SEMAGLUTIDE 2.4MG)
STEP 1 trial: average weight loss 14.9% of body weight over 68 weeks. Strong cardiovascular outcome evidence (SUSTAIN-6 programme). Most accessible option in India currently. Excellent first-line choice.
✓ MOUNJARO (TIRZEPATIDE)
SURMOUNT-1 trial: average weight loss 20.9% at highest dose over 72 weeks. Strongest clinical trial results in non-surgical obesity medicine history. Higher cost in India. Particularly effective for insulin resistance and type 2 diabetes.
These numbers are averages — individual responses vary significantly. Some patients achieve exceptional results on semaglutide; some show modest response to tirzepatide. The most appropriate medicine for a specific patient is determined by their metabolic profile, not by which product topped the trial leaderboard.
Side Effects — How Wegovy and Mounjaro Compare
Both medicines share a similar side effect profile given their overlapping GLP-1 mechanism. Nausea, reduced appetite, and mild fatigue in the first weeks are most common for both. These are dose-escalation effects — occurring when doses increase and typically resolving as the body adapts. Tirzepatide’s additional GIP mechanism does not meaningfully add to the side effect burden in clinical trials. Both medicines’ side effects are substantially reduced by careful gradual dose titration — which is exactly why supervision matters.
Cost and Access in India — The Honest Picture
Semaglutide (Wegovy equivalent) is currently more accessible and more affordable in India — accessed through specialist prescription at approximately ₹8,000–₹18,000 per month for medicine alone. Tirzepatide (Mounjaro) is accessible through specialist import prescription at higher cost. Both require doctor supervision for safety and optimal results. Neither should bepurchased from unregulated online sources.
Who Should Start With Wegovy — And Who Should Consider Mounjaro First
Wegovy / Semaglutide First Makes Sense When:
You are beginning GLP-1 treatment for the first time without a previous GLP-1 history. Cost and access are important practical considerations. A 15% weight loss target would achieve your clinical goals. Your metabolic profile does not show features strongly indicating tirzepatide’s GIP advantage.
Mounjaro / Tirzepatide May Be Indicated First When:
You have significant insulin resistance or type 2 diabetes where GIP’s additional insulinsensitising effect provides direct clinical benefit. You have had a partial but insufficient response to semaglutide previously. Your BMI or metabolic complexity makes maximum available efficacy the priority. Your doctor’s assessment of your metabolic profile indicates strong likelihood of tirzepatide advantage.
✓ INTELEDOC'S DECISION PROCESS
Your Inteledoc doctor reviews your full metabolic assessment findings, health history, previous treatment response, clinical goals, and practical considerations before recommending either medicine. The recommendation is personalised — not a commercial default. Book your assessment here.
💊 INTELEDOC PROGRAMME PLANS
3 Months Plan
GLP-1 Plan
₹4,500
Metabolic Plus
₹9,000
6 Months Plan
GLP-1 Plan
₹7,500
Metabolic Plus
₹15,000
12 Months Plan
GLP-1 Plan
₹12,000
Metabolic Plus
₹24,000
Frequently Asked Questions
Wegovy (semaglutide 2.4mg) is not yet formally CDSCO-approved as a distinct weight management product in India. Semaglutide at clinically appropriate weight-management doses is accessible through specialist prescription. The clinical treatment is available; the specific brand is not yet formally launched.
Yes — tirzepatide is accessible through specialist import prescription in India at Inteledoc and other obesity medicine clinics.
Yes — switching from semaglutide to tirzepatide based on clinical response is appropriate and standard practice. Your Inteledoc doctor manages the transition.
Both require the same gradual dose titration approach. Tirzepatide trial results show slightly faster weight loss once therapeutic doses are reached, but both show meaningful progress from weeks 8–12 in well-managed programmes.
Yes — tirzepatide’s GIP mechanism provides additional blood sugar control beyond GLP-1 alone, making it particularly valuable for patients with both obesity and type 2 diabetes.
Long-term maintenance data for both medicines shows weight regain when the medicine stops without adequate habit consolidation. Both require maintenance planning. Tirzepatide’s stronger initial loss may provide a higher maintenance baseline for some patients.
Your Inteledoc doctor reviews cardiovascular health as part of the pre-treatment assessment. Semaglutide has specific cardiovascular outcome trial evidence (SUSTAIN-6 showing cardiovascular risk reduction). Tirzepatide cardiovascular outcome data is emerging from ongoing trials.
Semaglutide is more affordable; tirzepatide is higher cost given import access. Exact costs
depend on dose and are discussed transparently at your first Inteledoc consultation.